CytomX Therapeutics, Inc. (CTMX) is a publicly traded Healthcare sector company. As of August 27, 2026, CTMX trades at $3.42 with a market cap of $734.32M and a P/E ratio of 0.00. CTMX moved +3.01% today. Year to date, CTMX is -21.88%; over the trailing twelve months it is +63.55%. Its 52-week range spans $0.40 to $8.21. Analyst consensus is strong buy with an average price target of $12.80. Rallies surfaces CTMX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for CTMX shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $3.42 |
| Market Cap | $734.32M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.21 |
| 52-Week Low | $0.40 |
| Volume | 55.98K |
| Avg Volume | 0 |
| Revenue (TTM) | $18.30M |
| Net Income | $-79.65M |
| Gross Margin | 0.00% |
5 analysts cover CTMX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.80.